Friday, 16 October 2026European Markets

POLIGHT Stock Bearish By 28% In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of POLIGHT (Oslo Børs Benchmark Index_GI: PLT.OL) dropped by a staggering 28.4% in 21 sessions from kr25.14 to kr18.00 at 13:39 EST on Thursday, after three successive sessions in a row of losses. Oslo Børs Benchmark Index_GI is sliding 0.51% to kr1,172.17, after three consecutive sessions in a row of gains.

POLIGHT's last close was kr18.80, 47.49% below its 52-week high of kr35.80.

About POLIGHT

poLight ASA develops optical lens for consumer devices and industrial applications. Its lens replicates the lens of the human eye enabling the implementation of autofocus functions for various applications. Its product portfolio includes Tunable Optical Lens (TLens) products; Tlens Silver and Tlens Silver Premium; and ASIC drivers that control the supply of variable voltage to Tlens products and makes them to change focus. The company offers its products for use in front and back camera phones; wearables, including AR/VR devices; tablet PCs; HD video cameras; drones; handheld devices; and barcode readers, as well for medical equipment. It has operations in Europe, Asia, and the United States. poLight ASA was founded in 2005 and is headquartered in Horten, Norway.

Earnings Per Share

As for profitability, POLIGHT has a trailing twelve months EPS of kr-5.93.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -31.52%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

POLIGHT's EBITDA is -93.75.

Moving Average

POLIGHT's worth is way below its 50-day moving average of kr23.79 and way below its 200-day moving average of kr22.34.

Yearly Top and Bottom Value

POLIGHT's stock is valued at kr18.00 at 13:39 EST, way below its 52-week high of kr35.80 and above its 52-week low of kr16.78.

Volume

Today's last reported volume for POLIGHT is 74559 which is 32.01% below its average volume of 71496.

More news about POLIGHT (PLT.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com